Carol F. Lippa , Thomas W. Smith , Kathleen C. Flanders
{"title":"Transforming Growth Factor-β: Neuronal and Glial Expression in CNS Degenerative Diseases","authors":"Carol F. Lippa , Thomas W. Smith , Kathleen C. Flanders","doi":"10.1006/neur.1995.0051","DOIUrl":null,"url":null,"abstract":"<div><p>We have previously shown that the brains of patients with Alzheimer's disease (AD) express transforming growth factor (TGF)-β2 in neurofibrillary tangle (NFT) -bearing neurons and reactive astrocytes. The present study was undertaken to determine whether other neurodegenerative diseases were also associated with an alteration of the TGF-β's. The immunohistochemical expression of TGF-β1, -2 and -3 was assessed in the brains of patients with progressive supranuclear palsy (<em>n</em>=2), amyotrophic lateral sclerosis (<em>n</em>=3), Lewy body disease (<em>n</em>=5), Parkinson's disease (<em>n</em>=1), Shy-Drager syndrome (<em>n</em>=1), Pick's disease (<em>n</em>=3), lobar atrophy (<em>n</em>=1), and corticobasal degeneration (<em>n</em>=2). Our results were compared to norms for controls (<em>n</em>=8). We found expression of TGF-β2 in both NFT bearing neurons and tangle-bearing glial cells in progressive supranuclear palsy and in neurons with age-related NFT formation. Widespread staining of reactive astrocytes for TGF-β2 was observed in all degenerative diseases. TGF-β1 and -3 staining was not selectively altered in these diseases. We conclude that induction of TGF-β2 may be an intrinsic part of the processes that underlie NFT formation and reactive gliosis in a variety of neurodegenerative diseases.</p></div>","PeriodicalId":19127,"journal":{"name":"Neurodegeneration","volume":"4 4","pages":"Pages 425-432"},"PeriodicalIF":0.0000,"publicationDate":"1995-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1006/neur.1995.0051","citationCount":"44","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurodegeneration","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1055833085700517","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 44
Abstract
We have previously shown that the brains of patients with Alzheimer's disease (AD) express transforming growth factor (TGF)-β2 in neurofibrillary tangle (NFT) -bearing neurons and reactive astrocytes. The present study was undertaken to determine whether other neurodegenerative diseases were also associated with an alteration of the TGF-β's. The immunohistochemical expression of TGF-β1, -2 and -3 was assessed in the brains of patients with progressive supranuclear palsy (n=2), amyotrophic lateral sclerosis (n=3), Lewy body disease (n=5), Parkinson's disease (n=1), Shy-Drager syndrome (n=1), Pick's disease (n=3), lobar atrophy (n=1), and corticobasal degeneration (n=2). Our results were compared to norms for controls (n=8). We found expression of TGF-β2 in both NFT bearing neurons and tangle-bearing glial cells in progressive supranuclear palsy and in neurons with age-related NFT formation. Widespread staining of reactive astrocytes for TGF-β2 was observed in all degenerative diseases. TGF-β1 and -3 staining was not selectively altered in these diseases. We conclude that induction of TGF-β2 may be an intrinsic part of the processes that underlie NFT formation and reactive gliosis in a variety of neurodegenerative diseases.